<DOC>
	<DOCNO>NCT01096186</DOCNO>
	<brief_summary>The purpose study determine long term safety clinical utility IPX066 subject Parkinson 's Disease .</brief_summary>
	<brief_title>An Open Label Extension Study Safety Clinical Utility IPX066 Subjects With Parkinson 's Disease</brief_title>
	<detailed_description>IPX066 intend chronic treatment motor symptom stag PD . This study design enroll subject successfully complete one follow study IPX066 : - IPX066-B08-05 ( A Placebo-Controlled Study Evaluate Safety Efficacy IPX066 Subjects Parkinson 's Disease ) - IPX066-B08-11 ( A Study Compare Pharmacokinetics Pharmacodynamics IPX066 Standard Carbidopa - Levodopa ) - IPX066-B09-02 ( A Study Evaluate Safety Efficacy IPX066 Advanced Parkinson 's Disease ) All participant give IPX066 9 month .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Each subject must meet follow inclusion criterion order enrol study : 1 . Successful completion study IPX066B0805 , IPX066B0811 , IPX066B0902 . 2 . In opinion Investigator , Parkinson 's disease diagnosis still valid subject remain eligible LD therapy . Each subject must free follow exclusion criterion order enrol study : 1 . Received investigational medication IPX066 trial within 4 week prior plan start treatment . 2 . Anticipates functional neurosurgical treatment PD ( e.g. , ablation deep brain stimulation ) study participation . 3 . Received within 4 week prior Baseline Visit plan take study participation : nonselective monoamine oxidase ( MAO ) inhibitor ( exception rasagiline ) . 4 . In opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>motor Symptoms</keyword>
	<keyword>efficacy</keyword>
	<keyword>IPX066</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>